ライフサイエンスコーパス: LT

1 LT for unauthorized immigrants is rare, and disparities

2 LT precession, an effect of relativistic frame dragging,

3 LT provides best long-term survival but is limited by or

4 LT-FH was 63% (standard error (s.e.) 6%) more powerful t

5 LT-HSCs are not found in bone marrow niches with the dee

6 d (2) total LT volume (<600, 600-1199, 1200+ LTs) in a retrospective cohort of 3248 adults with ALF l

7 The study included 14 LT centers and covered the period from January 2007 to D

8 Of 43,192 LT recipients, 43,026 (99.6%) were US citizens/residents

9 Among 73 206 LT patients, 658 (0.9%) were HIV-infected.

10 ); 0.63 (GA), 0.97 (RT), 2.00 (QT) and 2.41 (LT).

11 Median center outcome rates were 72.6% LT, 18.2% died/too sick, and 6.1% SS.

12 A total of 13 743 LT adult recipients in the United Network for Organ Shar

13 Among 811 LT patients, 766 underwent stress testing (94%) and 559

14 Activated LT-HSCs show heterogeneous responses, with some cells be

15 icies are present in most states with active LT centers and are associated with lower proportions of

16 nter study in the United States of 112 adult LT recipients with COVID-19.

17 Data from adult LT recipients with laboratory confirmed SARS-CoV2 infect

18 that Prdm16 preserves the function of adult LT-HSCs by promoting their quiescence.

19 ins in serum/plasma samples at month 3 after LT in recipients with preserved GFR who demonstrated sub

20 rd of patients require early admission after LT.

21 coronary artery bypass, and no aspirin after LT as independent risk factors for early occlusion.

22 association of DSA with complications after LT.

23 evels and development of complications after LT.

24 Occurrence of HLA class II DSA after LT is associated with graft cirrhosis and may indicate a

25 al/protein model (PRESERVE) that early after LT can predict future renal deterioration versus preserv

26 preservation of kidney function early after LT may lessen the incidence of CVE, which are an indepen

27 Patients with recurrent HCC after LT from 2002 to 2016 were reviewed from 3 transplant cen

28 of sirolimus on the recurrence of HCC after LT was investigated in a prospective randomized trial.

29 ients receiving aggregation inhibitors after LT.

30 Sirolimus use for >=3 months after LT for HCC independently reduced the hazard for death in

31 r disease, creatinine levels 12 months after LT significantly impacted the risk of long-term CVE.

32 CVE was 8% and 20% at 12 and 60 months after LT, respectively.

33 ncipally limited to the first 3 months after LT.

34 associated with graft loss at 3 months after LT.

35 Prediction of outcome after LT is limited by the lack of robust predictors of graft

36 eted therapies, POPH survival outcomes after LT in our cohort were modest and may reflect the need fo

37 Two patients tested positive after LT, and one patient died for COVID on POD 30.

38 All patients with HCC-recurrence after LT treated with SOR in 2 centers were included (January

39 rotects renal function only short-term after LT in the intention-to-treat analysis of this low MELD c

40 ients discontinued PA-targeted therapy after LT.

41 bitor Sirolimus (SIR) within 4-6 weeks after LT (group B, n = 261).

42 Although LT is associated with significantly increased survival c

43 that subclinical HEV infection exists among LT patients in this high-prevalence area.

44 The proportion of ReLT-KT among LT recipients continuously grew throughout the study per

45 nd characteristics related to survival among LT recipients with HIV infection were determined.

46 COP1 knockdown and ectopic expression of an LT-resistant MKK7-4 fusion protein.

47 5; P < .001; LV-LD: r = 0.696; P < .001; and LT-LD: r = 0.121; P = .039).

48 of LT and mortality models in cirrhosis and LT waitlisting, especially with an ageing population wit

49 lar when applying BOLT-LMM to GWAS, GWAX and LT-FH phenotypes.

50 y assist in optimizing graft utilization and LT outcomes.

51 However, as LT also promotes ETEC adhesion to intestinal epithelial

52 of long-term (beyond 12 mo) CVE were age at LT (hazard ratio [HR], 1.04; 95% confidence interval [CI

53 ics, donor, biochemical and clinical data at LT, immunosuppression (IS) and outcome.

54 The median MELD at LT was 20, 21, and 24 for ML-DR, ML-SR, and SL groups, r

55 Median MELD at LT was low with 10 (7-15) (group A) and 11 (8-15) (group

56 n model for end-stage liver disease score at LT was 7 ((interquartile range [IQR]: 6-11) and waiting

57 Adults with cirrhosis awaiting LT without hepatocellular carcinoma at nine LT centers i

58 tients with cirrhotic liver disease awaiting LT.

59 tlist dropout for patients with HCC awaiting LT.

60 t it is feasible to engage patients awaiting LT in an intensive aerobic exercise program with a signa

61 ic liver failure (ACLF) in patients awaiting LT, as well as early post-LT outcomes.

62 ry high risk of poor outcomes while awaiting LT.

63 , male gender, cardiovascular disease before LT, and cyclosporine A were associated with the risk of

64 Higher PVR before LT was associated with worse survival, as was monotherap

65 the practice of neoadjuvant treatment before LT.

66 o survived at least 3 months after bilateral LT (n = 157; age +/- SD: 54 +/- 13 y, male:female = 91:6

67 ometry during the first year after bilateral LT with 3-year posttransplant survival.

68 A significant proportion of bilateral LT patients do not achieve FVC>80% predicted.

69 lticenter retrospective study comparing cDCD LT with NRP and DBD LT.

70 UK Biobank (average N = 350,000) we compared LT-FH to genome-wide association without using family hi

71 ive study comparing cDCD LT with NRP and DBD LT.

72 All DCD LT performed at Mayo Clinic-Florida, Mayo Clinic-Arizona

73 icenter cohort study of adult deceased donor LT requiring AC.

74 ate allowing prompt access to deceased donor LT.

75 trations, waitlist mortality, deceased donor LTs (DDLT), and living donor LTs (LDLT) 3/15/2020-8/31/2

76 deceased donor LTs (DDLT), and living donor LTs (LDLT) 3/15/2020-8/31/2020 to expected values based

77 ETV4, and ETV5 in cells treated with either LT or the MEK1/2 inhibitor, U0126.

78 LTs in United States and Europe, with fewer LT for HCV disease over time.

79 lts with cirrhosis evaluated for their first LT in 2012 were followed through their clinical course w

80 Following LT, this results in a PD-1/CTLA4-dependent decrease in a

81 IPV and long-term outcome measures following LT.

82 es donor-specific T cell responses following LT and the influence of HCV eradication.

83 patients treated with VM become eligible for LT (44%; 95% confidence interval [CI], 31-58).

84 he ubiquitin E3 ligase that is essential for LT-induced c-Jun degradation.

85 iew of adult patients with ALD evaluated for LT at a single transplant center from January 1, 2010, t

86 Women were less likely to be listed for LT (10% versus 19%; P < 0.05).

87 We studied adults listed for LT at 2 transplant centers.

88 ve cohort of 3248 adults with ALF listed for LT at 92 centers nationally from 2002 to 2019.

89 t included all cirrhotic patients listed for LT between 2014 and 2017.

90 cohol-related liver disease (ALD) listed for LT during 2004-2017.

91 tal of 1012 HCV-HCC patients were listed for LT during the study period.

92 (UNOS) data, 14 844 HCC patients listed for LT from 2005 to 2015 were identified.

93 ross all diseases (for example, 690 loci for LT-FH versus 423 for GWAS); relative improvements were s

94 Thus, SB based matching rules for LT candidates might improve the survival of the LT popul

95 January 31, 2018, 131 adults waitlisted for LT with HEHE were identified by free-text entry.

96 A after neoadjuvant therapy may benefit from LT under research protocols.

97 OS from LT was 12.5 years, with a median time to LT of 7.5 month

98 HEHE recipients at 1-, 3-, and 5-years from LT was 88.6%, 78.9%, and 77.2%.

99 henolics (ppm) was, QT (10.91) > GA (7.33) > LT (4.10) > RT (3.90) whereas, Spanish whole green olive

100 was, GA (47.06) > RT (26.21) > QT (19.34) > LT (6.18).

101 l on case-control status and family history (LT-FH).

102 subset of the most quiescent long-term HSCs (LT-HSCs) and that is compatible with current intravital

103 The per protocol analysis identified LT recipients in group B with concomitant early CNI mini

104 In LT recipients with HCC presenting beyond MC, successful

105 (P = 0.007; OR, 7.93; 95% CI, 1.75-35.69) in LT recipients.

106 d with higher mortality and ICU admission in LT recipients with COVID-19.

107 concept of postoperative antiaggregation in LT requiring AC.

108 ogous immunity is necessarily detrimental in LT and provide an explanation for the association betwee

109 rehabilitation programs targeting frailty in LT patients of all ages.

110 Variables associated with liver injury in LT recipients were younger age (P = 0.009; odds ratio [O

111 incidence of acute liver injury was lower in LT recipients (47.5% vs. 34.6%; P = 0.037).

112 e accurately represent waitlist mortality in LT candidates.

113 irolimus for >=3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of

114 al outbreak, the cessation or a reduction in LT activity is a pragmatic requirement.

115 Three-year cumulative graft survival in LT recipients with and without HIV infection was 64.4% a

116 se reemergence and HEV viral transmission in LT patients.

117 We show that targeting specific domains in LTs can be lethal, which opens the possibility that LTs

118 mTOR inhibition increased LT protein expression for all 5 pathogenic polyomaviruse

119 We generated T cell lines from HCV-infected LT and non-LT patients before and after HCV eradication

120 raft and patient survival among HIV-infected LT recipients have shown improvement over time.

121 tic artery thrombosis <=14 days from initial LT was observed in HEHE versus non-HEHE patients (4.6% v

122 ysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4) (LTC(4)), LTD(4), and LTE(4), have different bi

123 rowing evidence supporting use of first-line LT.

124 imensions were statistically significant (LV-LT: r = 0.785; P < .001; LV-LD: r = 0.696; P < .001; and

125 by lymphoma-provided VEGFC and lymphotoxin (LT).

126 nsistently, RNA sequencing analysis of mouse LT-HSCs with and without Prdm16 deletion showed that Prd

127 LT without hepatocellular carcinoma at nine LT centers in the United States with LFI assessments wer

128 ed T cell lines from HCV-infected LT and non-LT patients before and after HCV eradication and quantif

129 Using SRTR data, we compared observed LT waitlist registrations, waitlist mortality, deceased

130 e terms, the incremental survival benefit of LT over resection or ablation was small, between 0.02 an

131 Non-invasive estimation of LT using the gas exchange threshold (non-linear increase

132 nt post-LT outcomes, justifying expansion of LT criteria.

133 s to understand to what extent the health of LT recipients' counties of residence influence long-term

134 ch as recipient and donor age, indication of LT.

135 ately characterized by direct measurement of LT, LD, and LV, rather than making assumptions based on

136 this study, we report long-term outcomes of LT for patients with HCC who were bridged/downstaged by

137 tratify the short- and long-term outcomes of LT recipients at the time of their evaluations irrespect

138 th graft loss, whereas more recent period of LT 2012-2015 (aHR, 0.58; P = 0.001) and donor with anoxi

139 and females in MWR have lower probability of LT.

140 The proportion of LT HIV-infected did not change over time (P-trend = 0.16

141 A static rate of LT among HIV-infected patients may reflect improvements

142 ctors potentially associated with receipt of LT versus medication.

143 or not there was a survival benefit (SB) of LT according to the quality of grafts assessed by the Do

144 We show that this subset of LT-HSCs resides close to both sinusoidal blood vessels a

145 Trends of LT were observed to be increased in patients > 65 years

146 condary aims were to determine the trends of LT, reasons for readmission, costs and predictors of cal

147 s has implications in determining urgency of LT and mortality models in cirrhosis and LT waitlisting,

148 tient characteristics associated with use of LT as primary therapy for glaucoma, including factors re

149 ts with HIV infection account for only 1% of LTs in United States and Europe, with fewer LT for HCV d

150 sted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrict

151 were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011.

152 outcome measures were (1) the proportion of LTs performed for unauthorized immigrants compared with

153 and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to state

154 itis has led to an increased number of older LT recipients with pre-LT chronic kidney disease (CKD).

155 We aimed to evaluate the impact of age on LT outcomes in NASH.

156 ectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary

157 determine the impact of multiple listing on LT rates.

158 improve patient selection for upfront LR or LT at initial diagnosis.

159 d policies in all states actively performing LT and linked state policies to prospectively collected

160 Pig LT was performed with livers from heart-beating donors o

161 Post-LT DAA was not related to increased risk of recurrence (

162 formed a cross-sectional study with 108 post-LT patients and found an IgG seroprevalence of 55.6%.

163 participants were treated pre-LT and 26 post-LT.

164 free survival was 42.8% at 4 years and post-LT survival was 87.9% at 5 years.

165 ts with decompensated liver disease and post-LT, with post-LT survival rates comparable to other indi

166 evels obtained during the first 15 days post-LT were collected.

167 was estimated during the first 15 days post-LT.

168 S state and (2) graft failure and death post-LT.

169 50% of patients, VM can be discontinued post-LT (95% CI, 38-62).

170 patients awaiting LT, as well as early post-LT outcomes.

171 Comparing era, post-LT mortality improved for HCC (adjusted HR, 0.55; 95% CI

172 We evaluated post-LT outcomes, predictors of down-staging, and the impact

173 d tumor burden and results in excellent post-LT outcomes, justifying expansion of LT criteria.

174 ls compared with the SCS-groups 3 hours post-LT (P = 0.006), on postoperative day (POD) 2 (P = 0.005)

175 growth factor-beta were higher 3 hours post-LT, on POD1 and on POD3.

176 n AFP and wait time may further improve post-LT outcomes in down-staging groups, especially given tha

177 cement therapy (RRT) in the first month post-LT.

178 , which are an independent predictor of post-LT death.

179 y lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and

180 ive review of the current literature on post-LT management of patients with HCC and identifies gaps i

181 no current evidence to support specific post-LT surveillance strategies, leading to significant heter

182 Rankings and graft and patient survival post-LT.

183 el and might pose clinical risks in the post-LT period.

184 pensated liver disease pre-LT and three post-LT.

185 Unadjusted post-LT patient and graft survival of HEHE patients was not d

186 Unadjusted post-LT survival of HEHE recipients at 1-, 3-, and 5-years fr

187 In this review of 223 patients with post-LT HCC recurrence, we found that increasing CETS does le

188 ensated liver disease and post-LT, with post-LT survival rates comparable to other indications.

189 Kaplan-Meier 3-year post-LT survival was 83.2% for Milan, 79.1% for UNOS-DS (P =

190 in nonimmune, nonviremic LTRs > 3 years post-LT.

191 astasis criteria at baseline pre-Y90 and pre-LT.

192 93.4%, 84.8%, 73.9% for the pre-LT DAA, pre-LT IFN, and antiviral naive groups, respectively (P < 0.

193 ied, 10 with decompensated liver disease pre-LT and three post-LT.

194 HR, 2.48; 95% CI, 1.21-5.05), history of pre-LT cardiovascular disease (HR, 2.19; 95% CI, 1.2-3.98),

195 isons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from th

196 survival was 93.4%, 84.8%, 73.9% for the pre-LT DAA, pre-LT IFN, and antiviral naive groups, respecti

197 Forty-two participants were treated pre-LT and 26 post-LT.

198 In patients with pre-LT cardiovascular disease, creatinine levels 12 months a

199 eatinine was restricted to patients with pre-LT cardiovascular disease.

200 eased number of older LT recipients with pre-LT chronic kidney disease (CKD).

201 Median time from primary LT to ReLT-KT was 151.3 (7.5-282.9) months.

202 pertension (61%, n=46/76), and 18% had prior-LT.

203 Predicted outcome probabilities (LT, died/too sick, spontaneous survival [SS]) were obtai

204 Among HCV patients, receiving a re-LT in the post-DAA era was associated with improved pati

205 Adult patients who underwent re-LT were identified in the Organ Procurement and Transpla

206 high comorbidity were less likely to receive LT (highest vs. lowest level of comorbidity: OR, 0.94; 9

207 s women were more likely than men to receive LT (OR, 1.42; 95% CI, 1.39-1.45).

208 in the analytic cohort, 658 (26.7%) received LT, 244 (11.5%) underwent resection, and 1317 (61.59%) r

209 ably improve a patient's chance of receiving LT and survival with the highest benefit for those with

210 Although the probability of receiving LT was significantly higher for the ML groups relative t

211 Patients receiving LT) for HCC are at a high risk for tumor recurrence.

212 diography alone is not reliable in screening LT patients for CAD.

213 Yet, selected LT recipients compliant with early CNI minimization and

214 the pandemic by considering leniency to some LT candidates with ALD who cannot access appropriate alc

215 rtic acid is missing, as is the case in some LTs (murein transglycosylase A) and expansins.

216 ne to better understand how to risk stratify LT candidates for recurrence of HCC following transplant

217 In vitro expression and turnover of large T (LT) proteins from BK, JC, Merkel cell, HPyV7 and trichod

218 s' counties of residence influence long-term LT outcomes.

219 pulation was increased, while the long-term (LT) population, side population and reconstitution capac

220 iated with LT outcomes, it also appears that LT recipient selection is effective at mitigating major

221 In vivo time-lapse imaging revealed that LT-HSCs at steady-state show limited motility.

222 be lethal, which opens the possibility that LTs are useful drug-targets.

223 curs at a metabolic rate often far above the LT and separates heavy from very heavy/severe-intensity

224 candidates might improve the survival of the LT population as a whole.

225 In this retrospective study, lens thickness (LT), lens diameter (LD), and lens volume (LV) were measu

226 tonian quadrupole moment and Lense-Thirring (LT) precession of the orbit resulting from rapid rotatio

227 n the arterial blood (the lactate threshold; LT).

228 Thus, LT-FH greatly increases association power when family hi

229 The human TNF/LT locus genes TNF, LTA, and LTB are expressed in a cell

230 grants is rare, and disparities in access to LT by state are present.

231 sis management and/or persistent barriers to LT.

232 were bridged, whereas 38 were downstaged to LT.

233 CC in the setting of bridging/downstaging to LT.

234 duals should be carefully evaluated prior to LT, considering their functional status, renal function,

235 underwent screening for SARS-CoV-2 prior to LT.

236 onsidering successful VM, 44% can proceed to LT, with half being able to postoperatively stop medicat

237 rom LT was 12.5 years, with a median time to LT of 7.5 months [interquartile range, 4.4-10.3].

238 Median time to LT was 12.8 months in long wait regions, 6.5 months in m

239 um: 20-39; high: 40+ listings) and (2) total LT volume (<600, 600-1199, 1200+ LTs) in a retrospective

240 Anthrax lethal toxin (LT) is a protease virulence factor produced by Bacillus

241 himera plus single-mutant heat-labile toxin [LT(R192G)] elicited strong serum anti-CfaE and anti-LTB

242 Lytic transglycosylases (LT) are enzymes involved in peptidoglycan (PG) remodelin

243 r failure (ALF), for which liver transplant (LT) can be lifesaving.

244 ral population and in post-liver transplant (LT) cases in several regions, including Thailand, with g

245 us (HCV) and improved post-liver transplant (LT) outcomes.

246 Network recently approved liver transplant (LT) prioritization for patients with hepatocellular carc

247 The aging of liver transplant (LT) recipients, the weighting of the model for end-stage

248 system; its effect on the liver transplant (LT) waitlist based on COVID-19 incidence has not been ch

249 (LFI), is associated with liver transplant (LT) waitlist mortality.

250 participants pre- or post-liver transplant (LT).

251 nants of health affect postliver transplant (LT) outcomes.

252 ator (VM) therapy and liver transplantation (LT) as treatment options.

253 ACLF-3 who underwent liver transplantation (LT) between 2007 and 2017 in 5 transplant centers were i

254 Liver transplantation (LT) centers should adapt to the pandemic by considering

255 In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covere

256 ntibodies (DSA) after liver transplantation (LT) for graft and patient survival is an ongoing controv

257 n patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory anal

258 Liver transplantation (LT) from controlled donation after circulatory death (cD

259 a contraindication to liver transplantation (LT) in most centers worldwide.

260 common indication for liver transplantation (LT) in the United States and in many parts of the world.

261 Liver transplantation (LT) in young patients is being performed with greater fr

262 hibitors (CNIs) after liver transplantation (LT) is associated with nephrotoxicity.

263 s (PSC), pre and post-liver transplantation (LT) is unclear.

264 l hypertension, prior liver transplantation (LT) or severe extra-hepatic manifestations.

265 the effect of age on liver transplantation (LT) outcomes in this population and whether it differs f

266 e waiting list before liver transplantation (LT) provides an opportunity to optimize recipient fitnes

267 raphic disparities in liver transplantation (LT) rates.

268 ar events (CVE) after liver transplantation (LT) remains scarce.

269 the first week after liver transplantation (LT) that is associated with graft loss at 3 months after

270 on the outcome of DCD liver transplantation (LT) utilizing livers with macrosteatosis.

271 (HCC) recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional tre

272 atients who underwent liver transplantation (LT).

273 recipient matching in liver transplantation (LT).

274 noma (HCC) listed for liver transplantation (LT).

275 patients referred for liver transplantation (LT).

276 tality while awaiting liver transplantation (LT).

277 y disease (CKD) after liver transplantation (LT).

278 sparities on access to lung transplantation (LT) in the United States.

279 lograft function after lung transplantation (LT).

280 ted States, nearly 30% of liver transplants (LT) are performed for hepatocellular carcinoma (HCC).

281 initiation <=0.5 y, n = 14) or late treated (LT; age at ART initiation 1-10 y, n = 6).

282 Patients undergoing LT following Y90 between 2004 and 2018 were included, wi

283 n 506 grafts from patients who had undergone LT and classified based on IRI severity (no, minimal, mi

284 patients developed ACLF, 54 (30%) underwent LT and 35 (19%) died.

285 g the 15-year period, 207 patients underwent LT after Y90.

286 NOS database of 3,819 patients who underwent LT from 2012 to 2015, classified as always within Milan

287 Indeed, here we show that ETEC use LT to up-regulate carcinoembryonic antigenrelated cell a

288 irus (HPV) assay (Onclarity) on the BD Viper LT platform using both contrived and clinical specimens.

289 Both VM and VM + LT improve pulmonary hemodynamics.

290 ies describing no treatment, VM, LT, or VM + LT in patients with PoPH.

291 eived VM only and patients who received VM + LT.

292 95% CI, 53-78) in patients treated with VM + LT.

293 control studies describing no treatment, VM, LT, or VM + LT in patients with PoPH.

294 cability of the frailty concept to the whole LT population and can guide the development of prehabili

295 there was significant correlation of AL with LT (r = -0.137; P = .002) and LD (r = 0.268; P < .001),

296 Although county health is associated with LT outcomes, it also appears that LT recipient selection

297 SB associated with LT was estimated using the sequential stratification met

298 degradation of c-Jun protein, combined with LT-mediated blockade of the JNK1/2 signaling pathway, in

299 patients were less likely to be treated with LT versus medication (>=81 years of age vs. 66-70 years

300 with decreased probability of treatment with LT, including cataract surgery (OR, 0.31; 95% CI, 0.30-0